Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy adult males and females, 18 to 55 years of age (inclusive) at the time of screening.~2. Body mass index (BMI) ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive).~3. Medically healthy with clinically insignificant screening results (e.g., laboratory profiles, medical histories, ECGs, physical examination) as deemed by the PI.~4. Non-tobacco/nicotine-containing product users for a minimum of Dose Study 6 months prior to Day 1.~5. Voluntarily consent to participate in the study.~6. Sexually abstinent or agree to use two approved methods of contraception.~Exclusion Criteria:~1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.~2. Positive urine drug/alcohol testing at screening or check-in (Day -1).~3. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).~4. History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.~5. Use of any over-the-counter (OTC) medication, including herbal products and vitamins, within the 7 days prior to Day 1. Up to 2 grams per day of acetaminophen is allowed for acute events at the discretion of the PI.~6. Blood donation or significant blood loss (i.e., \> 500 mL) within 56 days prior to Day 1.~7. Plasma donation within 7 days prior to Day 1.~8. Participation in another investigational clinical trial within 30 days prior to Day 1.~9. Subjects who have any abnormalities on laboratory values at screening or check-in (Day -1).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Single and multiple dose of RPX7009 (Type: EXPERIMENTAL): Single and multiple dose of RPX7009
- Single and multiple dose of RPX2014 (Type: EXPERIMENTAL): Single and multiple dose of RPX2014
- Normal Saline (Type: PLACEBO_COMPARATOR): Single and multiple dose of normal saline
- Combination RPX7009 and RPX2014 (Type: EXPERIMENTAL): Single and Multiple dose of Combination RPX7009 and RPX2014

Based on this trial design, predict the completion outcome and termination type (if applicable).